EGFR and neoplasm: Direct comparison of 86Y-labeled CHX-A”-DTPA-cetuximab and [86Y]Y-CHX-A”-DTPA-panitumumab in a malignant mesothelioma model suggested the superiority of [86Y]Y-CHX-A”-DTPA-panitumumab for PET-imaging of HER1 expression due to a slightly higher tumor uptake and significantly lower liver uptake [117,118].